January 23, 2026 – Alephoson Biopharmaceuticals Ltd. is pleased to announce the successful completion of our Series A funding round—A landmark multi-million-dollar USD investment led by Wuhan FIRHealth Capital Fund Partnership (Limited Partnership), with participation from Rui Guang Investment Limited. This milestone demonstrates strong investor confidence in our mission to transform ocular disease treatment through cutting-edge biological research and innovation.
The funding will enable us to expand our R&D pipeline, advance our proprietary Cell Penetration Protein Alteration (CePPA) technology platform, and accelerate the development of our lead therapeutic candidates toward clinical trials—bringing us closer to delivering transformative therapies for patients worldwide.
